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ABSTRACT
Hepatitis C virus (HCV) infection is a major public health problem. Up to 3% of the world’s population
is infected with HCV, and at least 200 000 adults in the UK carry the virus. Of those exposed to HCV,
80% become chronically infected, and at least 30% of carriers develop chronic liver disease, including
cirrhosis and hepatocellular carcinoma. This review provides an overview of selected features of the
molecular biology and pathogenesis of HCV infection, and thereafter discusses in detail the
epidemiology of HCV, the hepatic and extra-hepatic diseases caused by the virus, and the current
treatment options for both acute and chronic virus infection. The special cases of healthcare workers,
prison inmates and individuals coinfected with human immunodeficiency virus and HCV are
considered in detail.
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INTRODUCTION
Hepatitis C virus (HCV) is a major global health-
care problem. The WHO estimates that up to 3% of
the world’s population has been infected with the
virus, equating to more than 170 million carriers of
HCV worldwide. Within this broad estimate, there
is considerable variability in the prevalence of
infection [1]. The seroprevalence of HCV in the
USA is 1.8% in an unselected adult population [2],
whereas rates of up to 25% have been reported in
Egypt. In the UK, it is estimated that at least
200 000 adults carry the virus, most of whom are
unaware of their infection [3]. Of those individuals
exposed to HCV, 80% become persistently infec-
ted, and up to 30% of these develop progressive
liver disease, including cirrhosis and hepatocellu-
lar carcinoma (HCC) [4,5]. Indeed, HCV infection
is now the leading reason for liver transplantation
[6]. Therefore, HCV is already a major challenge to
healthcare services throughout the world, and is
likely to become an even greater burden during the
next two decades. In recognition of the importance
of this epidemic, the UK Department of Health
recently produced a ‘Hepatitis C Strategy for
England’, with the aims of identifying those
individuals who are chronically infected, and
providing specialist advice and treatment via
coordinated pathways of patient care [3].
THE VIRUS
HCV is a small, enveloped RNA virus which has
been allocated to a unique genus, designated
Hepacivirus, within the family Flaviridae. The
molecular biology of the virus has been reviewed
previously [7]. The HCV genome is a single-
stranded RNA molecule of positive polarity that
contains a single open reading frame with the
potential to encode a protein of c. 3000 amino-
acids in length. This open reading frame is
flanked by 5¢ and 3¢ non-coding regions, each of
which contains conserved RNA structures essen-
tial for the translation of virus protein and
genome replication. The HCV precursor protein
is processed by host-cell and virus proteases to
yield ten structural and non-structural (NS)
proteins (Fig. 1). The structural components of
the virion are the core protein and envelope
glycoproteins, E1 and E2. These proteins are
cleaved from the precursor by host-cell peptidases.
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The NS proteins, designated NS2 to NS5B, are
involved in the further processing of the pre-
cursor polypeptide and virus replication. The
structure of the HCV genome and the function of
individual proteins are described in detail in
Fig. 1.
In common with other RNA-dependent polym-
erases, the HCV RNA polymerase (NS5B) does
not have a proof-reading capability, and therefore
generates considerable genetic diversity. HCV is
divided into six genotypes, which differ from
each other by up to 30% in nucleotide sequence,
and a large and growing number of subtypes [7].
There is no consistent evidence that the genotype
affects the outcome of HCV infection. In contrast,
response to therapy clearly correlates with geno-
type. In addition to clustering into major and
minor genotypes, HCV evolves within individu-
als as a ‘quasi-species’ of closely related but
distinct genetic variants. The role of quasi-species
in the pathogenesis of disease remains controver-
sial, but it is likely that, as with human immuno-
deficiency virus (HIV), the capacity to generate
diversity is fundamental to the interaction of the
virus with the host.
Despite a detailed knowledge of the molecular
and structural biology of HCV, the pathogenesis
of infection remains unclear. This is, at least in
part, because there is no robust cell culture system
for propagation of the virus or, despite recent
advances, a widely accessible small animal model
of HCV disease [7]. Many studies have addressed
the role of individual virus proteins in trans-
formed cell lines and in transgenic animals [7,8].
These studies have proved frustratingly inconclu-
sive. For instance, HCV core protein can be shown
to both sensitise and desensitise different (and
sometimes the same) cell lines to apoptosis
induced by a range of cytokines, and to either
activate or inactivate cellular p53 and its regula-
tory pathway. Moreover, it causes tumours in
some transgenic mouse models, but not in others
[8]. The recent development of subgenomic ‘repl-
icons’ has provided a system for stable high-level
expression of virus RNAs and NS proteins [7].
This system, now permits production of struc-
tural proteins, but cannot couple RNA replication
with virion assembly. Furthermore, it can be
constructed with only a few virus isolates and
cell lines, and is of limited utility in the study of
virus–host interactions. Nonetheless, the replicon
system represents a major advance. Equally
encouraging is the drive to study the function of
HCV proteins in primary cells in carefully selec-
ted animal models. An excellent study conducted
in mice provided evidence that HCV core protein
protects primary hepatocytes from apoptosis
induced by cytokines expressed in the inflamed
liver, thereby suggesting a mechanism for both
virus persistence and the subsequent develop-
ment of malignant disease [9].
EPIDEMIOLOGY
HCV is endemic in most parts of the world. There
are, however, considerable temporal and geo-
graphical variations in the incidence and preval-
ence of infection. Age-specific analysis of
prevalence has identified three broad patterns of
transmission [1]. In the first of these, most HCV
infections are found in individuals aged
30–49 years, indicating that the risk of transmis-
sion was greatest in the recent past and affected
primarily young adults. This pattern predomin-
ates in the UK and the USA, where the principal
risk factor for the transmission of HCV is known
to be injecting drug use (IDU). In countries with
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Fig. 1. The structure of the hepatitis C virus genome [7].
The 5¢ non-coding region (NCR) contains four highly
conserved RNA domains and an internal ribosome entry
site. Structural proteins include core, which forms the virus
capsid, and the envelope glycoproteins E1 and E2. The
structural proteins are separated from the non-structural
(NS) proteins by a short peptide, P7 (not shown). NS
proteins are designated NS2 to NS5. NS4 and NS5 are each
processed further into two subunits, A and B. NS2 is a
component of the NS2–NS3 metalloprotease that autoca-
talyses cleavage of the NS2–NS3 junction; NS3 contributes
to the NS2–NS3 protease and contains a separate serine
protease that acts with co-factor NS4A to release the
remaining NS proteins. The C-terminal region of NS3
contains an RNA helicase and nucleotide triphosphatase
activity required for virus replication. NS5B is the RNA-
dependent RNA polymerase. The functions of NS4B and
NS5A in the virus life-cycle are unknown. The 3¢-NCR
contains a series of stable RNA stem–loop structures and a
polypyrimidine tract that is essential for genome replica-
tion.
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the second pattern, such as Japan, most infections
are found in the elderly, consistent with the risk of
HCV infection having been greater in the more
distant past. In countries with the third pattern,
such as Egypt, high rates of infection are observed
in all age groups. In the two latter groups,
contamination of equipment used to administer
vaccines and unsafe healthcare procedures may
be important means of transmission [1].
In contrast to the USA, where the National
Health and Nutrition Examination Survey found
that almost 2% of the population were HCV
antibody-positive [2], no study of HCV in an
unselected population has been performed in the
UK. Estimates based on studies of low-risk groups,
such as blood donors and antenatal women, sug-
gest a prevalence of up to 0.5% in the general
population. In contrast, a large study of injecting
drug users in England and Wales found an overall
prevalence of 30%, with rates of up to 70% in those
who had injected over the longest period [3]. Risk
factors for the acquisition of HCV in a UK
regional population are listed in Table 1. This
prospective study, incorporating five centres
within the Trent region of England, found that
HCV was most common among young adults,
over half of whom had been born in the 1960s or
later, and reported a male : female ratio of 2:1
[10]. This age and sex distribution is typical of
injecting drug users, and the Trent study con-
firmed that IDU was the most common risk factor
for infection. Approximately 50% of all infections
were associated with HCV genotype 1, but a
significant correlation was found between geno-
type 3 and infection by IDU. The second major
risk factor for HCV in this study was receipt of
blood components. The UK blood supply has,
however, been screened for antibodies to HCV
since 1993, and all blood components, other than
those required for use within 24 h of collection,
are now also screened for the presence of virus
RNA. As a consequence, the risk of exposure to
HCV through transfusion with blood or blood
components in the UK is extremely low [11].
In contrast to the clear and consistent evidence
linking parenteral exposure and HCV infection,
the role of sexual activity in spreading the virus
remains controversial. Prevalence studies of the
long-term sexual partners of patients with chronic
HCV infection have found an average rate of
infection of 1.5%, at least part of which may be
explained by other shared risk behaviour [12]. A
recent prospective study of 895 monogamous
heterosexual partners of HCV-infected individu-
als followed for 10 years (providing a follow-up
period of 8060 person-years) found no evidence of
sexual transmission of this virus [13]. However,
population-based studies have consistently
shown an association between high-risk sexual
behaviour and HCV infection [2,3], and this may
be particularly true for HIV-infected men who
have sex with men [14]. It is therefore likely that
the nature of sexual activity, together with HIV
coinfection, can increase the risk of sexual trans-
mission of HCV. HIV may also affect the transfer
of HCV from mother to child. The rate of vertical
transmission of HCV in the absence of HIV
infection is 6%, but is at least two-fold greater
in infants born to HIV- and HCV-coinfected
mothers [12]. Furthermore, while there is no
consistent evidence that elective Caesarian section
or avoidance of breast-feeding reduces transmis-
sion rates in mothers infected only with HCV,
these measures appear to reduce the risk of
transmission of HCV from coinfected mothers to
infants [15].
DISEASE
The natural history of HCV infection remains
surprisingly unclear. Large studies have sugges-
ted that up to 30% of infected individuals will
develop cirrhosis, leading to end-stage liver fail-
ure and HCC [4,5]. There is, however, consider-
able variation in the rate of progression of
HCV-associated liver fibrosis. Factors known to
be associated with the presence of advanced liver
disease on first biopsy are listed in Table 2. These
risk factors, however, are derived largely from
retrospective studies in which the dates of first
infection for many of the study cohort are
Table 1. Risk factors for hepatitis C virus infection among
769 patients in a cohort from a UK health region (data
presented in part previously by The Trent HCV Study
Group [10])
Risk factor No. (%) of patients
Intravenous drug use 509 (66)
Receipt of blood components 132 (17)
Non-professional tattoo 18 (2.3)
Sex with drug user 13 (1.7)
Healthcare worker 12 (1.6)
Born outside the UK 23 (3)
Tattoos 13 (1.7)
Non-professional ear piercing 3 (0.4)
None of the above 46 (6)
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unknown. Recent prospective studies have
addressed such limitations. The largest of these
examined paired liver biopsies from 214 HCV-
infected patients with predominantly mild dis-
ease [16], of whom 33% showed significant
progression of fibrosis over a median period of
2.5 years. Independent predictors of progression
on multivariant analysis were age at first biopsy,
and the presence of fibrosis on first biopsy.
Alcohol was not associated with fibrosis progres-
sion, but individuals who attend clinics for repeat
liver biopsies are a selected group with a gener-
ally low alcohol intake. The overall fibrosis
progression rate was 0.17 units ⁄ year, assessed
according to the Ishak index of histological
activity, indicating a mean time from infection
to cirrhosis of about 35 years. These results are
broadly comparable to those of other prospective
studies [17,18], although necroinflammation [17]
and interface hepatitis have also been found to
predict the progression of fibrosis [18]. All of
these results are consistent with the idea that
hepatic inflammation is the substrate that drives
fibrotic change. A further key conclusion arising
from this work is that fibrosis progression is not
linear, but accelerates with age, independent of
the likely duration of infection. This may explain
the relative absence of fibrotic liver disease in
young women infected by contaminated gamma-
globulin during pregnancy [19], and suggests that
the number of HCV-infected patients with cirrho-
sis of the liver will rise as the study cohorts age.
Several studies have suggested that the pres-
ence of steatosis on liver biopsy correlates with
the degree of fibrosis and the rate of disease
progression [20,21]. Interpretation of these obser-
vations is complicated by the contribution of both
virus and host factors, such as body mass index
and alcohol consumption, to steatosis. Steatosis is
more common following genotype 3 infection,
and may represent a direct cytopathic effect of
this virus [22]. Indeed, a multivariable logistic
regression analysis of 755 patients with HCV
infection found that steatosis was only predictive
of disease progression in patients infected with
genotype 3 [21]. The hypothesis that steatosis
provides additional substrate for lipid peroxida-
tion and amplifies hepatic inflammation in chro-
nic HCV infection is attractive. Nonetheless,
prospective studies have not found a correlation
between disease progression and steatosis
[16–18], and this remains an important area for
further study.
The natural history of compensated virus cir-
rhosis has not been well-defined. A prospective
study of 254 HCV-infected individuals with cir-
rhosis found that 30% developed at least one
major complication during a median follow-up
period of 93 months [23]. HCC was the most
common complication, with a cumulative inci-
dence of 28% at 10 years. Ascites, bleeding and
encephalopathy were also reported. Death from
liver disease occurred in 18% of the cohort, and
the most frequent single cause was HCC. These
results are broadly in accord with the largest
previous European study [24], and demonstrate
clearly that HCC is the most important complica-
tion of HCV-positive cirrhosis. This is consistent
with the outcome of a very large historical cohort
study which found that the relative risk of HCC in
cirrhosis of virus aetiology was much higher than
in cirrhosis associated with alcoholism (118.5 vs.
22.4) [25]. Once decompensation of HCV cirrhosis
has occurred, the 5-year survival rate is c. 50%,
with most deaths being liver-related [26,27].
In addition to causing chronic disease of the
liver, HCV infection has been linked to extra-
hepatic disease. Indeed, more than 30 extra-
hepatic disease manifestations have been
associated with HCV [27]. Most associations,
however, have been claimed by studies that are
either small or confounded by possible selection
bias, and a clear role for the virus has not yet been
established. In contrast, mixed cryoglobulinaemia
is associated unequivocally with HCV infection.
This may be a consequence of both general
stimulation of the production of polyclonal rheu-
matoid factor by chronic virus infection, and the
specific induction of monoclonal rheumatoid fac-
tor by HCV. More than 40% of individuals with
chronic HCV infection have cryoglobulins in the
peripheral blood, although only a minority devel-
op features of systemic vasculitis [27]. It is striking
that another potentially important extra-hepatic
disease linked to HCV is also a product of aberrant
B-cell regulation. Epidemiological studies from
Table 2. Factors established to predict the presence of
advanced fibrosis on first liver biopsy in chronic hepatitis
C virus infection [4,5,10]
Male sex
Duration of infection
Acquisition of infection at an age of > 40 years
High alcohol intake
Coinfection with hepatitis B virus
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Italy and Japan consistently show an increased
prevalence of HCV in patients with non-Hodg-
kin’s lymphoma of B-cell origin. However, similar
studies from other parts of Europe and the USA
have not confirmed this association, and a longi-
tudinal study of 2162 HCV-infected individuals in
Japan found a low incidence of non-Hodgkin’s
lymphoma of B-cell origin (reviewed in [27]).
Furthermore, although the virus has a limited
trophism for B-cells, HCV has not been found
consistently in lymphoma cells in vivo, and no
mechanism of lymphomagenesis in HCV infec-
tion has yet been described.
TREATMENT
Chronic hepatitis C virus infection
Monotherapy with interferon, the best available
treatment for HCV infection for many years,
produces a sustained response in < 20% of
patients. The introduction of combination therapy
with interferon-a, injected subcutaneously three-
times-weekly, and daily oral ribavirin was a
major advance [28]. This regimen produced a
sustained virus response (SVR), as defined by
undetectable virus RNA in the peripheral blood at
24 weeks after stopping therapy, in c. 40% of
previously untreated patients with chronic HCV
infection. More recently, combination therapy
using interferons modified by the addition of
either a 12-kDa or a 40-kDa polyethylene glycol
molecule (peginterferons) was found to be super-
ior to combination therapy involving standard
interferon or treatment with peginterferon alone
[29,30]. Although the two forms of peginterferon
are distinct pharmacologically, both are adminis-
tered weekly and produce sustained and cumu-
latively higher levels in the blood than
conventional three-times-weekly administration.
In a trial of 1530 treatment-naı¨ve patients with
chronic HCV infection, 12-kDa peginterferon a-2b
at a dose of 1.5 lg ⁄ kg plus ribavirin 800 mg
produced an overall SVR of 54%. The SVR for
genotype 1 was 42%, rising to c. 80% for geno-
type 2 or 3 infections [29]. In a similar, although
better designed, trial, 40-kDa peginterferon a-2a
at a dose of 180 lg plus ribavirin 1000 mg or
1200 mg (according to patient weight) achieved
an overall SVR of 56% (46% for genotype 1) [30].
In both studies, a high virus load and the presence
of severe fibrosis on liver biopsy correlated with a
poor response to therapy. There was some evi-
dence that the 40-kDa form was superior to the
12-kDa form in these hard-to-treat groups. The
relative merits of the two available peginterferons
are the subject of an ongoing comparative trial
and will not be discussed further. It has been
shown subsequently that genotype 2 and 3 dis-
ease can be treated with a 24-week course of
peginterferon plus ribavirin, and that no addi-
tional benefit is gained by extending therapy to
48 weeks [31]. It has also become clear that the
absence of at least a two-log drop in virus titre
after 12 weeks of therapy has a powerful negative
predictive value, and is an indication for stopping
treatment in cases of genotype 1 disease [29–31].
In response to these results, the UK National
Institute for Clinical Excellence has recommended
that combination therapy with peginterferons
should become the standard of care for the
treatment of individuals aged >18 years with
moderate-to-severe chronic HCV infection, de-
fined as histological evidence of significant scar-
ring (fibrosis) and ⁄ or significant necrotic
inflammation.
Despite these advances in the treatment of
chronic HCV infection, there remains a pressing
need for more effective therapies. Only c. 50% of
individuals with genotype 1 disease will respond
after combination therapy for 48 weeks. The
reason for the consistently lower response rates
of genotype 1 virus, in comparison to genotype 2
or 3, remains unclear. Response rates are likely to
be even lower in men, or in those who have a high
virus load or cirrhosis on liver biopsy, and may
decrease further with increasing age [29,30]. In
addition, there is evidence that African Ameri-
cans with genotype 1 disease have lower response
rates than Caucasian patients [32]. Conversely,
the high response rates achieved following the
treatment of patients with genotype 2 and 3
infection have prompted many hepatologists and
infectious disease physicians to treat disease
caused by genotypes 2 and 3 without performing
a liver biopsy. This policy will result in the early
treatment of many individuals with genotype 2
and 3 infection. The merits of such an approach
will become clearer following completion of the
UK Medical Research Council trial of early vs. late
treatment for HCV infection. At the other end of
the spectrum, the first analysis of the HALT-C
trial [33], evaluating the effectiveness of treating
previous non-responders, found that individuals
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who failed to respond to standard interferon,
given alone or as combination therapy, achieve an
SVR of 18% when treated with peginterferon and
ribavirin. Factors associated with an SVR were
infection with genotype 2 or 3, previous interferon
monotherapy, and lack of cirrhosis on liver
biopsy.
Acute HCV infection
Acute infection with HCV is now an uncommon
disease. Treatment of acute HCV infection, how-
ever, is a unique opportunity to prevent the
evolution to chronic infection, particularly as
several studies suggest that acute infection is
very much more sensitive to therapy than estab-
lished disease. The German Acute Hepatitis C
Therapy Group treated 44 patients with interferon
monotherapy during the acute phase of infection,
and achieved a remarkable SVR of 98% [34]. A
second German study treated only those patients
who remained HCV RNA-positive at 3 months
after the onset of hepatitis. This study achieved a
comparable overall virus clearance of 91% in 60
patients, as a consequence either of spontaneous
virus clearance or of treatment [35]. Interestingly,
52% of those with symptomatic disease cleared
the virus, whereas all asymptomatic patients
developed chronic infection before treatment.
The most recent study, conducted in Japan, found
that acute disease was exquisitely sensitive to
interferon treatment lasting 4 weeks, but that
delaying the initiation of treatment by 1 year
reduced the response rate significantly [36]. These
studies provide a rationale for the treatment of
acute disease, although it may be reasonable to
wait 3–6 months to allow symptomatic patients
the chance to clear virus spontaneously. The
reasons for the dramatic difference in the sensi-




The prevalence of HCV infection in healthcare
workers (HCWs) is comparable to that of the
general population. Although the overall rate of
HCV seroconversion following ‘sharps’ injury is
c. 2% (range 0–10%) [12], the risk of a HCW
transmitting the virus to a patient is very low in
practice, even during exposure-prone procedures
(EPPs). The policy of the UK Department of
Health is that individuals engaged in EPPs who
are found to be HCV RNA-positive must dis-
continue these activities. Furthermore, HCWs
who plan a career involving EPPs, such as general
surgery, must be screened and will not be
permitted to proceed if found to be HCV RNA-
positive. Practitioners already involved in EPPs
are, however, not legally obliged to undergo
screening for HCV. HCWs who have themselves
been exposed to HCV by ‘sharps’ injury have
been followed prospectively in the acute infection
studies discussed in the previous section [34–36].
The data from these studies suggest that there is
no rationale for post-exposure prophylaxis in a
HCW exposed to HCV, but that individuals
involved should be monitored carefully, and
treatment reserved for those who seroconvert
and fail to clear the virus.
HCV and HIV coinfection
The prevalence of coinfection with HCV and HIV
has been reported to lie between 15% and 70%,
with the highest prevalence in those individuals
who acquired HIV by IDU [37,38]. The European
Association for the Study of the Liver and the
American Association for the Study of Liver
Diseases both recommend that all HIV-positive
individuals should be screened for HCV [37].
Coinfection with HIV affects all stages of HCV
infection adversely. Indeed, end-stage liver dis-
ease associated with HCV infection is now one of
the major causes of morbidity and mortality in
HIV-infected individuals [37,38]. In contrast, the
effect of HCV on progression and response to
therapy of HIV disease remains unclear. It is,
however, evident that infection with HCV is
associated with a 2–10-fold increased risk of
developing hepatoxicity in response to highly
active anti-retroviral therapy (HAART) [37,38].
Early retrospective studies identified individual
drugs, such as nevirapine, as particularly toxic in
coinfected individuals, but evidence from pros-
pective studies emphasises that HCV is an addi-
tional risk factor for hepatoxicity, irrespective of
the HAART regimen used [38]. It is therefore of
particular importance to monitor liver function
tests meticulously in coinfected individuals
receiving HAART. Moderate or severe liver dam-
age, as defined by transaminase levels of up to
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5–10-fold the normal upper limit (grade 3),
usually resolves without any need to discontinue
therapy, but a rise to > 10-fold the normal upper
limit (grade 4) is an indication to discontinue
treatment. There is a theoretical risk that ribavirin
may promote the mitochondrial toxicity
syndrome associated with nucleoside reverse
transcriptase inhibitors, and patients must be
monitored at regular intervals for this complica-
tion [37,38]. Overall, however, > 80% of coinfect-
ed individuals continue to benefit from HAART.
The first large randomised controlled trials of
combination therapy with peginterferon in HCV-
and HIV-coinfected individuals have now been
published [39,40]. The results of the largest of these
trials (APRICOT) [39] provide strong evidence
that treatment with 40-kDa peginterferon a-2a and
ribavirin for 12 months is effective in the treatment
of coinfected individuals with stable disease and
CD4 counts of > 200 ⁄ lL, or 100–200 ⁄ lL with an
HIV virus load of < 5000 copies ⁄mL. Furthermore,
in the 286 subjects who received it, combination
therapy for HCV did not appear to affect the
control of HIV adversely, or to exacerbate the side-
effects of HAART. Overall, SVRs were 40% (29%
genotype 1) vs. 12% (7% genotype 1) for standard
interferon and ribavirin, and 20% (14% geno-
type 1) for peginterferon alone. These results are
encouraging, but drop-out rates were higher than
for mono-infected individuals; indeed, 15% of
patients failed to complete therapy for 48 weeks
because of adverse events or laboratory abnorm-
alities. It is also of note that coinfected patients
may be at greater risk of hepatic decompensation,
and those with a Child–Pugh score of six or greater
should be treated with extreme caution. None-
theless, the APRICOT trial and ACTG A5071 [40]
provide a rationale for the use of combination
therapy including the 40-kDa peginterferon for
individuals with stable HIV disease who are
coinfected with HCV.
Prisons
Most injecting drug users pass through the prison
system at some time. It has been estimated that
30% of men who have injected drugs have done
so in prison, and that 75% of those who inject in a
prison environment share equipment [3]. The
prison population is therefore at high risk of HCV
infection, and transmission within prisons is
known to occur. Estimates of seroprevalence vary
according to the methods used to sample the
population, but 37% of prisoners surveyed by
unlinked anonymous testing were positive for
HCV [41]. The ‘Hepatitis C Strategy for England’
[3] recognises prisons as a controlled environment
in which treatment can be offered to a population
with a high prevalence of both HCV infection and
co-factors for disease progression, such as high
alcohol consumption and coinfection with hepa-
titis B virus. It has, however, proved difficult to
forge and maintain effective links between pris-
ons and specialist hepatitis services. A thorough
attempt to establish outreach clinics in a UK
prison cluster proved effective in delivering
health education, but had little effect on the
identification or eradication of HCV in the prison
population [41].
STRATEGIES FOR CONTROL OF HCV
Strategies for the prevention and control of HCV
infection have been reviewed extensively [12] and
are the main focus of the ‘Hepatitis C Strategy for
England’ [3] and the follow-up document ‘Hepa-
titis C Action Plan’ [42]. These strategies arise
from growing knowledge of the epidemiology of
HCV and recognition of the efficacy of treatment
in reducing the burden of disease in infected
populations. They include the following:
• Intensified health promotion to discourage new
IDU, including drugs education in schools.
• Prevention of infection in current injectors by
provision of needle exchanges and harm reduc-
tion services.
• Increased professional and public awareness of
HCV, with the particular aim of increasing the
numbers of individuals tested for HCV infec-
tion.
Table 3. Suggested components of an ideal multidiscipli-
nary clinical network for the management of hepatitis C
infection in the UK (adapted from [3])
Specialist services for viral hepatitis, comprising:
Clinicians experienced in the diagnosis and management of viral hepatitis,
including hepatologists and infectious disease physicians
Clinical nurse specialists
An accredited virology laboratory
Access to interventional radiology
Access to expert liver pathology
Other secondary care services, e.g., genitourinary medicine
Primary care
Drug and alcohol services
Prison medical services
Charities and voluntary groups
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• Formation of multidisciplinary clinical net-
works to coordinate the care of HCV-positive
patients and provide antiviral treatment accord-
ing to National Institute for Clinical Excellence
guidelines. The components of an ideal multi-
disciplinary clinical network are listed in
Table 3.
• The creation of a coherent plan for the man-
agement of HCV in prisons.
Reduction in the incidence of new HCV infec-
tions and improved management of established
infection, through multidisciplinary clinical net-
works or otherwise, are particularly critical if the
predicted sustained increase in the number of
patients with cirrhosis and HCC as a consequence
of chronic HCV infection is to be reversed. A
European study estimated that a 50% decline in
the incidence of HCV from 1990 will still lead to
an increase of 120–150% in HCV-related mortality
in the course of the next 30 years [43]. In order to
achieve a reduction in HCV-related mortality in
this time period, new cases of HCV will need to
be virtually eliminated [43]. Such dramatic chan-
ges will require a major revision of the current
approach to the management of this important
infection.
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